05/19/2026
The goal isn't weight loss. It's recomposition.
When you pair a growth hormone peptide with a GLP-1 like semaglutide or tirzepatide, the objective shifts: lose fat while protecting lean muscle mass.
That distinction matters. GLP-1 monotherapy can strip lean tissue alongside fat — including the glute and skeletal muscle loss patients now call "Ozempic butt."
The peptides that defend against it fall into two categories:
GROWTH HORMONE SECRETAGOGUES — signal your pituitary to produce its own GH:
→ CJC-1295 / Ipamorelin — the top muscle-saver. CJC-1295 extends GH release; Ipamorelin stimulates the pulse. Together: lean muscle retention, better sleep, metabolic support.
→ Sermorelin — a shorter-acting GHRH that preserves muscle and energy during rapid weight loss.
FAT-TARGETING FRAGMENTS — built strictly for fat loss:
→ AOD-9604 — a modified GH fragment that stimulates lipolysis directly, without impacting blood sugar or muscle, ensuring lost weight comes from fat.
Same scale number, very different body underneath. Recomposition is a clinical strategy — and GH peptide pairing belongs under physician oversight.
Free physician-led webinar on May 20 at 6:30 PM CT — comment PROTOCOL for the link.
—
Prestige 2.0 · Physician-Led Metabolic Medicine